The WW domain-containing oxidoreductase (WWOX) gene, encodes a tumor suppressor located on 16q23.1, spanning FRA16D, one of the most active common fragile sites in the human genome, that is altered in numerous types of cancer. WWOX’s alteration in these myriad cancers is due to disparate mechanisms including loss of heterozygosity, homozygous deletion and epigenetic changes. In vitro, WWOX has been found to be reduced or absent in numerous cancer cell lines and WWOX restoration has been found to inhibit tumor cell growth and invasion. Wwox knockout mice developed femoral focal lesions resembling osteosarcomas within one month of their life and aging Wwox heterozygous mice have an increased incidence of spontaneous lung and mammary tumors as well as B-cell lymphomas. We herein review WWOX’s role that has been unearthed thus far in different types of malignancies, its clinical significance and future implications.
SalahZAqeilanRHuebnerK. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol2010; 6: 249–59.
2.
BednarekAKLaflinKJDanielRLLiaoQHawkinsKAAldazCM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res2000; 60: 2140–45.
3.
RiedKFinnisMHobsonLMangelsdorfMDayanSNancarrowJKWoollattEKremmidiotisGGardnerAVenterDBakerERichardsRI. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet2000; 9: 1651–63.
4.
ChangNSPrattNHeathJSchultzLSleveDCareyGBZevotekN. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem2001; 276: 3361–70.
5.
BeroukhimRMermelCHPorterDWeiGRaychaudhuriSDonovanJBarretinaJBoehmJSDobsonJUrashimaMMc HenryKTPinchbackRMLigonAHChoYJHaeryLGreulichHReichMWincklerWLawrenceMSWeirBATanakaKEChiangDYBassAJLooAHoffmanCPrensnerJLiefeldTGaoQYeciesDSignorettiSMaherEKayeFJSasakiHTepperJEFletcherJATaberneroJBaselgaJTsaoMSDemichelisFRubinMAJannePADalyMJNuceraCLevineRLEbertBLGabrielSRustgiAKAntonescuCRLadanyiMLetaiAGarrawayLALodaMBeerDGTrueLDOkamotoAPomeroySLSingerSGolubTRLanderESGetzGSellersWRMeyersonM. The landscape of somatic copy-number alteration across human cancers. Nature2010; 463: 899–905.
6.
WatanabeAHippoYTaniguchiHIwanariHYashiroMHirakawaKKodamaTAburataniH. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res2003; 63: 8629–33.
7.
ChangNSSchultzLHsuLJLewisJSuMSzeCI. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene2005; 24: 714–23.
8.
FabbriMIliopoulosDTrapassoFAqeilanRICimminoAZanesiNYendamuriSHanSYAmadoriDHuebnerKCroceCM. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A2005; 102: 15611–6.
9.
IliopoulosDFabbriMDruckTQinHRHanSYHuebnerK. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res2007; 13: 268–74.
10.
QinHRIliopoulosDSembaSFabbriMDruckTVoliniaSCroceCMMorrisonCDKleinRDHuebnerK. A role for the WWOX gene in prostate cancer. Cancer Res2006; 66: 6477–81.
11.
BeckerSMarkovaBWiewrodtRHoffarthSHahnelPSPleinerSSchmidtLHBreitenbuecherFSchulerM. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. J Thorac Oncol2011; 6: 1976–83.
12.
GourleyCPaigeAJTaylorKJWardCKuskeBZhangJSunMJanczarSHarrisonDJMuirMSmythJFGabraH. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res2009; 69: 4835–42.
13.
AqeilanRITrapassoFHussainSCostineanSMarshallDPekarskyYHaganJPZanesiNKaouMSteinGSLianJBCroceCM. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A2007; 104: 3949–54.
Del MareSSalahZAqeilanRI. WWOX: its genomics, partners, and functions. J Cell Biochem2009; 108: 737–45.
19.
HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell2011; 144: 646–74.
20.
EkizogluSMuslumanogluMDalayNBuyruN. Genetic alterations of the WWOX gene in breast cancer. Med Oncol2012; 29: 1529–35.
21.
LiuCJShenWGPengSYChengHWKaoSYLinSCChangKW. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int J Cancer. Epub ahead of print 3 July 2013.
22.
YendamuriSKurokiTTrapassoFHenryACDumonKRHuebnerKWilliamsNNKaiserLRCroceCM. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res2003; 63: 878–81.
23.
AqeilanRIKurokiTPekarskyYAlbaghaOTrapassoFBaffaRHuebnerKEdmondsPCroceCM. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res2004; 10: 3053–8.
24.
PaigeAJTaylorKJTaylorCHillierSGFarringtonSScottDPorteousDJSmythJFGabraHWatsonJE. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A2001; 98: 11417–22.
25.
GuoWDongZDongYGuoYKuangGYangZ. Genetic and epigenetic alterations of WWOX in the development of gastric cardia adenocarcinoma. Environ Mol Mutagen2013; 54: 112–23.
26.
FinnisMDayanSHobsonLChenevix-TrenchGFriendKRiedKVenterDWoollattEBakerERichardsRI. Common chromosomal fragile site FRA16D mutation in cancer cells. Hum Mol Genet2005; 14: 1341–9.
27.
SinghVSharmaPCapalashN. DNA methyltransferase inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets. Epub ahead of print 18 March 2013.
28.
IliopoulosDGulerGHanSYJohnstonDDruckTMcCorkellKAPalazzoJMcCuePABaffaRHuebnerK. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene2005; 24: 1625–33.
29.
WangXChaoLJinGMaGZangYSunJ. Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumour Biol2009; 30: 8–14.
30.
SevereNDieudonneFXMariePJ. E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis2013; 4: e463–e463.
31.
MahajanNPWhangYEMohlerJLEarpHS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res2005; 65: 10514–23.
32.
KessonEMAllardiceGMGeorgeWDBurnsHJMorrisonDS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ2012; 344: e2718–e2718.
33.
HigginbothamKSBreyerJPMcReynoldsKMBradleyKMSchuylerPAPlummerWDFreudenthalMETrentham-DietzANewcombPAParlFFSandersMEPageDLEganKMDupontWDSmithJR. A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. Cancer Epidemiol Biomarkers Prev2012; 21: 1565–73.
34.
AbdeenSKSalahZKhawaledSAqeilanRI. Characterization of WWOX inactivation in murine mammary gland development. J Cell Physiol. Epub ahead of print 18 December 2012.
35.
GulerGUnerAGulerNHanSYIliopoulosDHauckWWMcCuePHuebnerK. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer2004; 100: 1605–14.
36.
DriouchKPrydzHMoneseRJohansenHLidereauRFrengenE. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene2002; 21: 1832–40.
37.
BednarekAKKeck-WaggonerCLDanielRLLaflinKJBergsagelPLKiguchiKBrennerAJAldazCM. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res2001; 61: 8068–73.
38.
AqeilanRIPalamarchukAWeigelRJHerreroJJPekarskyYCroceCM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res2004; 64: 8256–61.
39.
HuebnerKCroceCM. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer2003; 88: 1501–6.
40.
GulerGUnerAGulerNHanSYIliopoulosDMcCuePHuebnerK. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int2005; 55: 471–8.
41.
GulerGHimmetogluCJimenezREGeyerSMWangWPCostineanSPilarskiRTMorrisonCSurenDLiuJChenJKamalJShapiroCLHuebnerK. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat2011; 129: 421–32.
42.
AqeilanRIDonatiVGaudioENicolosoMSSundvallMKorhonenALundinJIsolaJSudolMJoensuuHCroceCMEleniusK. Association of Wwox with ErbB4 in breast cancer. Cancer Res2007; 67: 9330–36.
43.
PuttiTCEl-RehimDMRakhaEAPaishCELeeAHPinderSEEllisIO. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol2005; 18: 26–35.
44.
NunezMILudes-MeyersJAbbaMCKilHAbbeyNWPageRESahinAKlein-SzantoAJAldazCM. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat2005; 89: 99–105.
45.
PluciennikEKusinskaRPotemskiPKubiakRKordekRBednarekAK. WWOX—the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol2006; 32: 153–7.
46.
WangXChaoLMaGChenLZangYSunJ. The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. J Cancer Res Clin Oncol2011; 137: 271–8.
47.
GulerGIliopoulosDGulerNHimmetogluCHayranMHuebnerK. Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res2007; 13: 6115–21.
48.
Gothlin EremoAWegmanPStalONordenskjoldBFornanderTWingrenS. Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients. Oncol Rep2013; 29: 1467–74.
49.
JemalABrayFCenterMMFerlayJWardEFormanD. Global cancer statistics. CA Cancer J Clin2011; 61: 69–90.
50.
QinHRIliopoulosDNakamuraTCostineanSVoliniaSDruckTSunJOkumuraHHuebnerK. Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res2007; 5: 957–65.
51.
HongQSzeCILinSRLeeMHHeRYSchultzLChangJYChenSJBoackleRJHsuLJChangNS. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PloS One2009; 4: e5755–e5755.
52.
WatsonJEDoggettNAAlbertsonDGAndayaAChinnaiyanAvan DekkenHGinzingerDHaqqCJamesKKamkarSKowbelDPinkelDSchmittLSimkoJPVolikSWeinbergVKParisPLCollinsC. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene2004; 23: 3487–94.
53.
LangeEMBeebe-DimmerJLRayAMZuhlkeKAEllisJWangYWaltersSCooneyKA. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate2009; 69: 385–91.
54.
ChengILevinAMTaiYCPlummerSChenGKNeslund-DudasCCaseyGRybickiBAWitteJS. Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer2012; 51: 66–76.
55.
DonatiVFontaniniGDell'OmodarmeMPratiMCNutiSLucchiMMussiAFabbriMBasoloFCroceCMAqeilanRI. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res2007; 13: 884–91.
56.
ZhouYXuYZhangZ. Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer. J Huazhong Univ Sci Technol Med Sci2005; 25: 162–5.
57.
BaykaraODemirkayaAKaynakKTanjuSTokerABuyruN. WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC). Tumour Biol2010; 31: 315–20.
58.
ZhouYLLiYCShouFLiuCQPuYTangH. Reversing effect of exogenous WWOX gene expression on malignant phenotype of primary cultured lung carcinoma cells. Chin Med J2010; 123: 615–20.
59.
HuangDQiuFYangLLiYChengMWangHMaGWangYHuMJiWZhouYLuJ. The polymorphisms and haplotypes of WWOX gene are associated with the risk of lung cancer in southern and eastern Chinese populations. Mol Carcinog. Epub ahead of print 12 June 2012.
60.
YangLLiuBHuangBDengJLiHYuBQiuFChengMWangHYangRYangXZhouYLuJ. A functional copy number variation in the WWOX gene is associated with lung cancer risk in Chinese. Hum Mol Genet. Epub ahead of print 7 February 2013.
61.
CantorJPIliopoulosDRaoASDruckTSembaSHanSYMcCorkellKALakshmanTVCollinsJEWachsbergerPFriedbergJSHuebnerK. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. International journal of cancer. J Int Cancer2007; 120: 24–31.
62.
FabbriMGarzonRCimminoALiuZZanesiNCallegariELiuSAlderHCostineanSFernandez-CymeringCVoliniaSGulerGMorrisonCDChanKKMarcucciGCalinGAHuebnerKCroceCM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A2007; 104: 15805–10.
63.
KimuraMTakenobuHAkitaNNakazawaAOchiaiHShimozatoOFujimuraYKosekiHYoshinoIKimuraHNakagawaraAKamijoT. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells. Cancer Sci2011; 102: 983–90.
64.
GereigeRKumarM. Bone lesions: benign and malignant. Pediatr Rev2010; 31: 355–62. quiz 363.
65.
KurekKCDel MareSSalahZAbdeenSSadiqHLeeSHGaudioEZanesiNJonesKBDeYoungBAmirGGebhardtMWarmanMSteinGSSteinJLLianJBAqeilanRI. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res2010; 70: 5577–86.
66.
AbdeenSKDel MareSHussainSRemailehMASalahZHaganJRawahnehMPuXARussellSSteinJLSteinGSLianJBAqeilanRI. Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol. Epub ahead of print 18 December 2012.
67.
YangJCogdellDYangDHuLLiHZhengHDuXPangYTrentJChenKZhangW. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett2010; 291: 31–8.
68.
DinizMGBorgesERPimentaFJDe Mesquita NettoACDe MarcoLGomezRSGomesCC. Evidence of molecular alterations in the tumour suppressor gene WWOX in benign and malignant bone related lesions of the jaws. Oncol Rep2011; 25: 499–502.
69.
AqeilanRIHassanMQde BruinAHaganJPVoliniaSPalumboTHussainSLeeSHGaurTSteinGSLianJBCroceCM. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem2008; 283: 21629–39.
70.
NathanSSPereiraBPZhouYFGuptaADombrowskiCSoongRPhoRWSteinGSSalto-TellezMCoolSMvan WijnenAJ. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep2009; 36: 153–8.
71.
Del MareSKurekKCSteinGSLianJBAqeilanRI. Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res2011; 1: 585–94.
72.
MayoSCNathanHCameronJLOlinoKEdilBHHermanJMHiroseKSchulickRDChotiMAWolfgangCLPawlikTM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer2012; 118: 2674–81.
73.
KurokiTYendamuriSTrapassoFMatsuyamaAAqeilanRIAlderHRattanSCesariRNolliMLWilliamsNNMoriMKanematsuTCroceCM. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res2004; 10: 2459–65.
74.
NakayamaSSembaSMaedaNAqeilanRIHuebnerKYokozakiH. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci2008; 99: 1370–76.
75.
BloomstonMKneileJButterfieldMDillhoffMMuscarellaPEllisonECMelvinWSCroceCMPichiorriFHuebnerKFrankelWL. Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features. Ann Surg Oncol2009; 16: 2331–8.
76.
NakayamaSSembaSMaedaNMatsushitaMKurodaYYokozakiH. Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas. Br J Cancer2009; 100: 1438–43.
77.
MaedaNSembaSNakayamaSYanagiharaKYokozakiH. Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch2010; 457: 423–32.
78.
YanJZhangMZhangJChenXZhangX. Helicobacter pylori infection promotes methylation of WWOX gene in human gastric cancer. Biochem Biophys Res Commun2011; 408: 99–102.
79.
TakeuchiTAdachiYNagayamaT. A WWOX-binding molecule, transmembrane protein 207, is related to the invasiveness of gastric signet-ring cell carcinoma. Carcinogenesis2012; 33: 548–54.
80.
AqeilanRIHaganJPAqeilanHAPichiorriFFongLYCroceCM. Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res2007; 67: 5606–10.
81.
NunezMIRosenDGLudes-MeyersJHAbbaMCKilHPageRKlein-SzantoAJGodwinAKLiuJMillsGBAldazCM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer2005; 5: 64–64.
82.
GourleyCPaigeAJTaylorKJScottDFrancisNJRushRAldazCMSmythJFGabraH. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol2005; 26: 1681–9.
83.
XiongZHuSWangZ. Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells. J Huazhong Univ Sci Technol Med Sci2010; 30: 365–9.
84.
LanCChenggangWYulanBXiaohuiDJunhuiZXiaoW. Aberrant expression of WWOX protein in epithelial ovarian cancer: a clinicopathologic and immunohistochemical study. Int J Gynecol Pathol2012; 31: 125–32.
85.
PaigeAJZucknickMJanczarSPaulJMeinCATaylorKJStewartMGourleyCRichardsonSPerrenTGanesanTSSmythJFBrownRGabraH. WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. Eur J Cancer2010; 46: 818–25.
86.
YanHCZhangJ. Effects of sodium valproate on the growth of human ovarian cancer cell line HO8910. Asian Pacific J Cancer Prev2012; 13: 6429–33.
LaiFJChengCLChenSTWuCHHsuLJLeeJYChaoSCSheenMCShenCLChangNSSheuHM. WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin Cancer Res2005; 11: 5769–77.
89.
TsaiCWLaiFJSheuHMLinYSChangTHJanMSChenSMHsuPCHuangTTHuangTCSheenMCChenSTChangWCChangNSHsuLJ. WWOX suppresses autophagy for inducing apoptosis in methotrexate-treated human squamous cell carcinoma. Cell Death Dis2013; 4: e792–e792.
90.
JennerMWLeonePEWalkerBARossFMJohnsonDCGonzalezDChiecchioLDachs CabanasEDagradaGPNightingaleMProtheroeRKStockleyDElseMDickensNJCrossNCDaviesFEMorganGJ. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood2007; 110: 3291–300.
91.
ZaidiSKvan WijnenAJLianJBSteinJLSteinGS. Targeting deregulated epigenetic control in cancer: cancer epigenomics as a platform for risk assessment, early detection, targeted therapy and potential for relapse. J Cell Physiol. Epub ahead of print 15 April 2013.
92.
Cancer Genome Atlas Research N, Genome sequencing centresBroadIGetzGGabrielSBCibulskisKLanderESivachenkoASougnezCLawrenceMWashington University in StLKandothCDoolingDFultonRFultonLKalicki-VeizerJMcLellanMDO'LaughlinMSchmidtHWilsonRKYeKDingLMardisER, Genome characterization centres: British Columbia, CancerAAllyABalasundaramMBirolIButterfieldYSCarlsenRCarterCChuAChuahEChunHJDhallaNGuinRHirstCHoltRAJonesSJLeeDLiHIMarraMAMayoMMooreRAMungallAJPlettnerPScheinJESipahimalaniPTamAVarholRJGordon RobertsonABroadICherniackADPashtanISaksenaGOnofrioRCSchumacherSETabakBCarterSLHernandezBGentryJSalvesenHBArdlieKGetzGWincklerWBeroukhimRGabrielSBMeyersonMHarvard MedicalSBWomen's HospitalMDACCHadjipanayisALeeSMahadeshwarHSParkPProtopopovARenXSethSSongXTangJXiRYangLZengDKucherlapatiRChinLZhangJUniversity of NorthCTodd AumanJBaluSBodenheimerTBudaENeil HayesDHoyleAPJefferysSRJonesCDMengSMieczkowskiPAMoseLEParkerJSPerouCMRoachJShiYSimonsJVSolowayMGTanDTopalMDWaringSWuJHoadleyKAUniversity of SouthernCJohnsHBaylinSBBootwallaMSLaiPHTricheTJJrVan Den BergDJWeisenbergerDJLairdPWShenH, Genome data analysis centres, BroadIChinLZhangJGetzGChoJDicaraDFrazerSHeimanDJingRLinPMallardWStojanovPVoetDZhangHZouLNobleMLawrenceMInstitute for SystemsBReynoldsSMShmulevichIMemorial Sloan-Kettering CancerCArman AksoyBAntipinYCirielloGDresdnerGGaoJGrossBJacobsenALadanyiMRevaBSanderCSinhaROnur SumerSTaylorBSCeramiEWeinholdNSchultzNShenRUniversity of CaliforniaSCBIBenzSGoldsteinTHausslerDNgSSzetoCStuartJBenzCCYauCUniversity of TexasMDACCZhangWAnnalaMBroomBMCasasentTDJuZLiangHLiuGLuYUnruhAKWakefieldCWeinsteinJNZhangNLiuYBroaddusRAkbaniRMillsGB, Biospecimen core resource, Nationwide Children'sHAdamsCBarrTBlackADBowenJDeardurffJFrickJGastier-FosterJMGrossmanTHarperHAHart-KothariMHelselCHobensackAKuckHKneileKLeraasKMLichtenbergTMMcAllisterCPyattRERamirezNCTablerTRVanhooseNWhitePWiseLZmudaETissue source sitesABarnabasNBerry-GreenCBlancVBoiceLButtonMFarkasAGreenAMackenzieJNicholsonDBritish Columbia CancerAKallogerSEBlake GilksCCedars-Sinai MedicalCKarlanBYLesterJOrsulicSChristianaCBorowskyMCadungogMCzerwinskiCHuelsenbeck-DillLIacoccaMPetrelliNRabenoBWitkinGCurelineNemirovich-DanchenkoEPotapovaORotinDDukeUBerchuckAGynecologic OncologyGBirrerMDisaiaPMonovichLInternational GenomicsCCurleyEGardnerJMalleryDPennyRMayoCDowdySCWinterhoffBDaoLGostoutBMeuterATeomanAMemorial Sloan-Kettering CancerCDaoFOlveraNBogomolniyFGargKSoslowRALevineDA, Center NNBRCR, AbramovMOntario TumourBBartlettJMKodeeswaranSParfittJSt Petersburg AcademicUMoiseenkoFUniversity HealthNClarkeBAUniversity ofHGoodmanMTCarneyMEMatsunoRKUniversity of NorthCFisherJHuangMRathmellWKThorneLVan LeLUniversity ofPDhirREdwardsRElishaevEZornKUniversity of TexasMDACCBroaddusRWashington University School ofMGoodfellowPJMutchD, Disease analysis working g, SchultzNLiuYAkbaniRCherniackADCeramiEWeinholdNShenHHoadleyKAKahnABBellDWPollockPMWangCDAWShinbrotEKarlanBYBerchuckADowdySCWinterhoffBGoodmanMTGordon RobertsonABeroukhimRPashtanISalvesenHBLairdPWNobleMStuartJDingLKandothCBlake GilksCSoslowRAGoodfellowPJMutchDBroaddusRZhangWMillsGBKucherlapatiRMardisERLevineDA, Data coordination c, AyalaBChuALJensenMAKothiyalPPihlTDPontiusJPotDASnyderEESrinivasanDKahnAB, Project team, National CancerIMills ShawKRShethMDavidsenTEley MartinLFGDemchokJAYangLNational Human Genome ResearchIGuyerMSOzenbergerBASofiaHJWritingcKandothCSchultzNCherniackADAkbaniRLiuYShenHGordon RobertsonAPashtanIShenRBenzCCYauCLairdPWDingLZhangWMillsGBKucherlapatiRMardisERLevineDA. Integrated genomic characterization of endometrial carcinoma. Nature2013; 497: 67–73.
93.
ParkSWLudes-MeyersJZimonjicDBDurkinMEPopescuNCAldazCM. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer2004; 91: 753–9.
94.
AdercaIMoserCDVeerasamyMBani-HaniAHBonilla-GuerreroRAhmedKShireACazanaveSCMontoyaDPMettlerTABurgartLJNagorneyDMThibodeauSNCunninghamJMLaiJPRobertsLR. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol2008; 49: 373–83.
95.
HuBSTanJWZhuGHWangDFZhouXSunZQ. WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J Gastroenterol2012; 18: 3020–26.
96.
LiYPWuCCChenWTHuangYCChaiCY. The expression and significance of WWOX and beta-catenin in hepatocellular carcinoma. APMIS2013; 121: 120–26.
97.
PluciennikENowakowskaMWujcickaWISitkiewiczAKazanowskaBZielinskaEBednarekAK. Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis. Oncol Rep2012; 28: 1417–22.
DincerNTezelGGSungurAHimmetogluCHuebnerKGulerG. Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncol2010; 46: 195–9.
100.
KoslaKPluciennikEKurzykAJesionek-KupnickaDKordekRPotemskiPBednarekAK. Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J Neuro-oncol2011; 101: 207–13.
101.
ChiangMFYehSTLiaoHFChangNSChenYJ. Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother2012; 66: 433–38.
102.
IshiiHVecchioneAFurukawaYSutheesophonKHanSYDruckTKurokiTTrapassoFNishimuraMSaitoYOzawaKCroceCMHuebnerKFurukawaY. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res2003; 1: 940–47.
103.
CuiZLinDChengFLuoLKongLXuJHuJLanF. The role of the WWOX gene in leukemia and its mechanisms of action. Oncol Rep2013; 29: 2154–62.
